FIELD: biotechnology.
SUBSTANCE: disclosed are an antagonist antibody molecule which specifically binds to TNFR2 on a target cell, thereby blocking TNF-α binding with TNFR2 and blocks signal transmission through TNFR2; an isolated nucleotide sequence encoding an antibody molecule; an antibody expression plasmid comprising a nucleotide sequence; a virus for expression and extracellular release of an antibody containing a nucleotide sequence or a plasmid, and a cell as a carrier for antibody delivery, as well as their use in medicine in the treatment of cancer or infection caused by an intracellular pathogen. Also disclosed are a pharmaceutical composition for treating cancer or an infection caused by an intracellular pathogen in patients and methods of treating cancer and an infection caused by an intracellular pathogen in patients.
EFFECT: invention can be used in treating cancer or infections caused by intracellular pathogens.
48 cl, 21 dwg, 11 tbl, 7 ex
| Title | Year | Author | Number |
|---|---|---|---|
| BISPECIFIC ANTIBODIES TO CD25 AND Fc GAMMA-RECEPTOR FOR ELIMINATION OF TUMOR-SPECIFIC CELLS | 2017 |
|
RU2759970C2 |
| HUMANISED ANTIBODIES TO OX40 AND METHODS FOR USE THEREOF | 2015 |
|
RU2709742C2 |
| ANTIBODIES TO PD-1 AND METHODS OF THEIR APPLICATION | 2015 |
|
RU2701797C2 |
| ANTIBODIES AGAINST OX40 AND METHODS OF THEIR APPLICATION | 2012 |
|
RU2562874C1 |
| NEW ANTIBODIES AND NUCLEOTIDE SEQUENCES AND THEIR USE | 2019 |
|
RU2802450C2 |
| ANTIBODY AGAINST TNFR2 AND ITS APPLICATION | 2020 |
|
RU2793165C1 |
| HUMAN VISTA ANTIBODIES AND THEIR APPLICATION | 2017 |
|
RU2746994C2 |
| ANTI-ICOS ANTIBODIES | 2017 |
|
RU2764548C2 |
| NEW ANTIBODY COMBINATION AND ITS USE | 2019 |
|
RU2800035C2 |
| METHODS OF TREATING CANCER USING ANTAGONISTS BINDING TO PD-1 AXIS AND TIGIT INHIBITORS | 2014 |
|
RU2702108C2 |
